Arcus Biosciences, Inc.

This phase 3 trial tests whether adding the experimental drug quemliclustat to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 610 participants who have not had prior treatment for advanced disease will receive either the drug combo or a pl…

This study tests whether combining new drugs with or without standard chemotherapy can help people with advanced stomach, gastroesophageal junction, or esophageal cancer. About 332 participants will receive different treatment combinations to see if they shrink tumors and improve…

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …

This study tests a combination of two immune-boosting drugs (zimberelimab and domvanalimab) as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The goal is to see if the combo helps control the cancer longer tha…

This study tests whether adding a new drug (domvanalimab) to standard chemotherapy and an immunotherapy (zimberelimab) helps people with advanced stomach, gastroesophageal junction, or esophageal cancer live longer compared to the current standard treatment (nivolumab plus chemot…

This study tests a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers like lung, colon, or breast cancer that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose. This is an early-phas…

This early-stage study tests a new drug called AB680 combined with three other medications (zimberelimab, nab-paclitaxel, and gemcitabine) in people with advanced pancreatic cancer that has not been treated before. The main goals are to check safety and find the right dose. About…